Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Videos Contact Meet the Team Advertise Search Become a Member Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma Download PDF Copy Add News Medical on Google as a preferred source Hebrew University of Jerusalem Jul 9 2026 Reviewed Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of the most aggressive form of brain cancer: resistance to chemotherapy. The study shows that an experimental compound called BA-101 can restore the effectiveness of the standard drug temozolomide (TMZ) by blocking a biological process known as nitrosative stress, which helps tumors survive and resist treatment. In preclinical models, the combination therapy slowed tumor growth, reduced the cancer's ability to spread, and increased cancer cell death, opening the door to a potential new approach for treating drug-resistant glioblastoma.